Compare NVST & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVST | WGS |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.6B |
| IPO Year | 2019 | N/A |
| Metric | NVST | WGS |
|---|---|---|
| Price | $29.47 | $91.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | $23.85 | ★ $138.13 |
| AVG Volume (30 Days) | ★ 3.5M | 862.3K |
| Earning Date | 02-05-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.28 | 0.07 |
| Revenue | ★ $2,719,500,000.00 | $402,190,000.00 |
| Revenue This Year | $2.81 | $41.17 |
| Revenue Next Year | $3.54 | $23.94 |
| P/E Ratio | ★ $104.02 | $1,146.19 |
| Revenue Growth | 8.32 | ★ 50.50 |
| 52 Week Low | $14.22 | $55.17 |
| 52 Week High | $29.28 | $170.87 |
| Indicator | NVST | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 79.71 | 34.96 |
| Support Level | $22.75 | $81.55 |
| Resistance Level | $24.48 | $101.94 |
| Average True Range (ATR) | 0.96 | 6.78 |
| MACD | 0.45 | -0.11 |
| Stochastic Oscillator | 95.26 | 38.30 |
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.